4.4 Article

Urinary complement proteins and risk of end-stage renal disease: quantitative urinary proteomics in patients with type 2 diabetes and biopsy-proven diabetic nephropathy

Journal

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
Volume 44, Issue 12, Pages 2709-2723

Publisher

SPRINGER
DOI: 10.1007/s40618-021-01596-3

Keywords

Complement; Urinary proteomics; Diabetic nephropathy; End-stage renal disease

Funding

  1. National Natural Science Foundation of China [81970626]
  2. Key Research and Development Project of Sichuan Science Technology Department [19ZDYF1273]
  3. Popularization Project of the Science and Technology Project of the Sichuan Health Planning Committee [19PJ250]

Ask authors/readers for more resources

The study investigated the association between urinary complement proteins and renal outcome in biopsy-proven diabetic nephropathy. Results showed that the abundance of certain urinary complement proteins correlated with the decline of renal function and progression to end-stage renal disease in diabetic patients, suggesting that therapeutic targeting of the complement pathway may help alleviate the progression of diabetic nephropathy.
Purpose To investigate the association between urinary complement proteins and renal outcome in biopsy-proven diabetic nephropathy (DN). Methods Untargeted proteomic and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional analyses and targeted proteomic analysis using parallel reaction-monitoring (PRM)-mass spectrometry was performed to determine the abundance of urinary complement proteins in healthy controls, type 2 diabetes mellitus (T2DM) patients, and patients with T2DM and biopsy-proven DN. The abundance of each urinary complement protein was individually included in Cox proportional hazards models for predicting progression to end-stage renal disease (ESRD). Results Untargeted proteomic and functional analysis using the KEGG showed that differentially expressed urinary proteins were primarily associated with the complement and coagulation cascades. Subsequent urinary complement proteins quantification using PRM showed that urinary abundances of C3, C9, and complement factor H (CFAH) correlated negatively with annual estimated glomerular filtration rate (eGFR) decline, while urinary abundances of C5, decay-accelerating factor (DAF), and CD59 correlated positively with annual rate of eGFR decline. Furthermore, higher urinary abundance of CFAH and lower urinary abundance of DAF were independently associated with greater risk of progression to ESRD. Urinary abundance of CFAH and DAF had a larger area under the curve (AUC) than that of eGFR, proteinuria, or any pathological parameter. Moreover, the model that included CFAH or DAF had a larger AUC than that with only clinical or pathological parameters. Conclusion Urinary abundance of complement proteins was significantly associated with ESRD in patients with T2DM and biopsy-proven DN, indicating that therapeutically targeting the complement pathway may alleviate progression of DN.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available